ProShare Advisors’s Rocket Pharmaceuticals RCKT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $52.7K | Sell |
15,421
-1,722
| -10% | -$5.73K | ﹤0.01% | 1840 |
|
|
2026
Q1 | $61.4K | Sell |
17,143
-3,125
| -15% | -$12.4K | ﹤0.01% | 1765 |
|
|
2025
Q4 | $71.1K | Buy |
20,268
+1,933
| +11% | +$6.62K | ﹤0.01% | 1912 |
|
|
2025
Q3 | $59.8K | Sell |
18,335
-2,887
| -14% | -$9.09K | ﹤0.01% | 1916 |
|
|
2025
Q2 | $52K | Sell |
21,222
-271
| -1% | -$1.37K | ﹤0.01% | 1989 |
|
|
2025
Q1 | $143K | Sell |
21,493
-1,354
| -6% | -$13.4K | ﹤0.01% | 1768 |
|
|
2024
Q4 | $287K | Buy |
22,847
+5,035
| +28% | +$75.8K | ﹤0.01% | 1664 |
|
|
2024
Q3 | $329K | Buy |
17,812
+3,802
| +27% | +$77.9K | ﹤0.01% | 1402 |
|
|
2024
Q2 | $302K | Sell |
14,010
-3,604
| -20% | -$82.8K | ﹤0.01% | 1287 |
|
|
2024
Q1 | $475K | Buy |
17,614
+1,468
| +9% | +$41.7K | ﹤0.01% | 1117 |
|
|
2023
Q4 | $484K | Buy |
16,146
+3,593
| +29% | +$79.3K | ﹤0.01% | 1053 |
|
|
2023
Q3 | $257K | Buy |
12,553
+50
| +0.4% | +$909 | ﹤0.01% | 1297 |
|
|
2023
Q2 | $248K | Buy |
12,503
+431
| +4% | +$8.71K | ﹤0.01% | 1401 |
|
|
2023
Q1 | $207K | Sell |
12,072
-1,102
| -8% | -$21.6K | ﹤0.01% | 1427 |
|
|
2022
Q4 | $258K | Buy |
13,174
+2,793
| +27% | +$51.4K | ﹤0.01% | 1326 |
|
|
2022
Q3 | $167K | Buy |
10,381
+338
| +3% | +$5.27K | ﹤0.01% | 1449 |
|
|
2022
Q2 | $139K | Sell |
10,043
-4,365
| -30% | -$52K | ﹤0.01% | 1550 |
|
|
2022
Q1 | $229K | Sell |
14,408
-3,675
| -20% | -$63.5K | ﹤0.01% | 1802 |
|
|
2021
Q4 | $394K | Sell |
18,083
-721
| -4% | -$19.7K | ﹤0.01% | 1618 |
|
|
2021
Q3 | $562K | Sell |
18,804
-2,892
| -13% | -$105K | ﹤0.01% | 1138 |
|
|
2021
Q2 | $961K | Buy |
21,696
+3,353
| +18% | +$146K | ﹤0.01% | 1062 |
|
|
2021
Q1 | $814K | Buy |
18,343
+2,275
| +14% | +$125K | ﹤0.01% | 1114 |
|
|
2020
Q4 | $881K | Buy |
16,068
+2,998
| +23% | +$109K | ﹤0.01% | 941 |
|
|
2020
Q3 | $299K | Sell |
13,070
-373
| -3% | -$9.19K | ﹤0.01% | 1178 |
|
|
2020
Q2 | $281K | Buy |
+13,443
| New | +$242K | ﹤0.01% | 1262 |
|
|
2020
Q1 | – | Sell |
-14,924
| Closed | -$340K | – | 1494 |
|
|
2019
Q4 | $340K | Sell |
14,924
-2,146
| -13% | -$35.8K | ﹤0.01% | 1267 |
|
|
2019
Q3 | $199K | Sell |
17,070
-115
| -0.7% | -$1.43K | ﹤0.01% | 1446 |
|
|
2019
Q2 | $258K | Sell |
17,185
-133
| -0.8% | -$2.32K | ﹤0.01% | 1317 |
|
|
2019
Q1 | $304K | Buy |
17,318
+1,614
| +10% | +$25.5K | ﹤0.01% | 1250 |
|
|
2018
Q4 | $233K | Buy |
+15,704
| New | +$261K | ﹤0.01% | 1289 |
|
|
2016
Q4 | – | Sell |
-4,671
| Closed | -$177K | – | 1750 |
|
|
2016
Q3 | $177K | Sell |
4,671
-781
| -14% | -$24.6K | ﹤0.01% | 1364 |
|
|
2016
Q2 | $162K | Buy |
5,452
+601
| +12% | +$21.1K | ﹤0.01% | 1465 |
|
|
2016
Q1 | $144K | Sell |
4,851
-458
| -9% | -$13.7K | ﹤0.01% | 1475 |
|
|
2015
Q4 | $241K | Buy |
+5,309
| New | +$231K | ﹤0.01% | 1435 |
|
Other funds holding RCKT
RI
NM
MC
ProShare Advisors's RCKT Position: Q2 2026 in Review
ProShare Advisors reduced its Rocket Pharmaceuticals (RCKT) stake by 10% in Q2 2026, selling an estimated $5.73K and leaving 15,421 shares worth $52.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1840.
ProShare Advisors first reported a position in RCKT in Q4 2015 and has held it in 34 quarters since. The position peaked at $961K in Q2 2021. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.
- ProShare Advisors held 15,421 shares of Rocket Pharmaceuticals worth $52.7K as of Q2 2026.
- ProShare Advisors sold 1,722 Rocket Pharmaceuticals shares in Q2 2026, an estimated $5.73K.
- Rocket Pharmaceuticals made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1840 holding.
- ProShare Advisors first reported a position in Rocket Pharmaceuticals in Q4 2015 and has held it in 34 quarters since.
- ProShare Advisors's Rocket Pharmaceuticals position peaked at $961K in Q2 2021.
- 180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.
Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.